Fernando Mateus - 17 Feb 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role: SENIOR VICE PRESIDENT
Signature: /s/ Fernando Mateus by Jessica H. Paik, Attorney-in-Fact
Issuer symbol: ABT
Transactions as of: 17 Feb 2023
Net transactions value: -$126,167
Form type: 4
Filing time: 22 Feb 2023, 18:03:48 UTC
Previous filing: 27 Jul 2022
Next filing: 02 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABT	Common shares without par value	Award	$0	+10,560	+73%	$0.000000	25,063	17 Feb 2023	Direct	F1
transaction	ABT	Common shares without par value	Tax liability	$55,291	-518	-2.1%	$106.74	24,545	19 Feb 2023	Direct
transaction	ABT	Common shares without par value	Tax liability	$70,875	-664	-2.7%	$106.74	23,881	21 Feb 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABT	Option (right to buy)	Award	$0	+41,648		$0.000000	41,648	17 Feb 2023	Common Shares	41,648	$106.24	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2	Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,882 on February 17, 2024, 13,883 on February 17, 2025, and 13,883 on February 17, 2026.